- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Fractyl Health, Inc.: Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide | 1 | GlobeNewswire (USA) | ||
| 19.05. | Fractyl Health advances gene therapy for diabetes treatment | 1 | Investing.com | ||
| 19.05. | Fractyl Health treibt Gentherapie für Diabetesbehandlung voran | 2 | Investing.com Deutsch | ||
| 19.05. | Fractyl Health, Inc.: Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes | 141 | GlobeNewswire (Europe) | First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect... ► Artikel lesen | |
| 19.05. | FRACTYL HEALTH, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.05. | Fractyl Health, Inc.: Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 | 87 | GlobeNewswire (Europe) | Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D- potentially simultaneously addressing durability, adherence... ► Artikel lesen | |
| FRACTYL HEALTH Aktie jetzt für 0€ handeln | |||||
| 14.05. | Fractyl Health Partners with Forge for Rejuva Gene Therapy Development | 1 | Contract Pharma | ||
| 14.05. | Fractyl signals accelerated enrollment for REMAIN-1 study while advancing Rejuva clinical milestones | 1 | Seeking Alpha | ||
| 13.05. | Fractyl Health, Inc.: Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates | 324 | GlobeNewswire (Europe) | REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1... ► Artikel lesen | |
| 13.05. | FRACTYL HEALTH, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 28.04. | Fractyl Health, Inc.: Fractyl Health to Present Compelling Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 02.04. | Fractyl Health, Inc. (GUTS): Insider Were Buying In Q1 2025 | 1 | Insider Monkey | ||
| 01.04. | FRACTYL HEALTH, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.03. | FRACTYL HEALTH, INC. - 8-K, Current Report | - | SEC Filings | ||
| 09.03. | Fractyl Health, Inc. Common Stock (NASDAQ:GUTS) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
| 03.03. | Fractyl Health, Inc. Loss At -$24.97 Mln In Q4 | - | RTTNews | ||
| 03.03. | Fractyl Health GAAP EPS of -$0.52 misses by $0.18 | 3 | Seeking Alpha | ||
| 03.03. | Fractyl Health, Inc.: Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates | 26 | GlobeNewswire (Europe) | Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full... ► Artikel lesen | |
| 03.03. | FRACTYL HEALTH, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 03.02. | Fractyl Health announces layoffs as it pivots to gene therapy | 2 | MassDevice |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 99,15 | +1,69 % | BioNTech: Milliardendeal mit Bristol Myers Squibb - Aktie schießt ins Plus | BioNTechs Aktien schießen in der US-Vorbörse am Montag regelrecht nach oben: Aktuell werden 106,10 Dollar notiert nach einem NASDAQ-Schlusskurs bei 95,81 Dollar vom Freitag. Der Grund für den Kursanstieg... ► Artikel lesen | |
| CUREVAC | 3,980 | +2,00 % | CureVac mit SPEZIAL-MELDUNG: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
| AMGEN | 252,35 | +0,34 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
| NOVAVAX | 6,251 | -0,16 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| BIOGEN | 115,80 | +0,17 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
| MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt
16.05.2025 /... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,800 | +0,63 % | Could Viking Therapeutics Become the Next Eli Lilly? | ||
| INTELLIA THERAPEUTICS | 6,774 | +0,83 % | Canaccord Genuity lowers Intellia stock price target to $54 | ||
| BIOCRYST PHARMACEUTICALS | 9,610 | -0,52 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| TEMPUS AI | 54,68 | -0,62 % | XFRA NEW INSTRUMENTS AVAILABLE ON 03.06.2025 | The following instruments on XETRA do have their first trading 03.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.06.2025
Aktien
1 US88023B1035 Tempus AI Inc.
2 KYG9482E1180... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 34,950 | +0,81 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,300 | +2,52 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
| EXELIXIS | 37,860 | +2,32 % | Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,890 | -0,63 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
| VAXART | 0,341 | -3,78 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders |
FRACTYL HEALTH INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FRACTYL HEALTH INC finden Sie auf Wallstreet Online.